Biogen Begins Phase III Felzartamab Study for Third Kidney Disease

• click to rate

  Posted by Two Blokes Jul 1 - Filed in Stock - 3 views
  
  BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with no approved therapies.